

Chapter 58

REFERENCES

1. Demikhov V. Experimental transplantation of an additional heart in the dog. *Bull Exp Biol Med (Russia)*. 1950;1:241.
2. Konstantinov IE. A mystery of Vladimir P. Demikhov: the 50th anniversary of the first intrathoracic transplantation. *Ann Thorac Surg*. 1998;65:1171-1177.
3. Carrel A, Guthrie CC. The transplantation of vein and organs. *Am Med*. 1905;10:101.
4. Cooley DA, Bloodwell RD, Hallman GL. Cardiac transplantation for advanced acquired heart disease. *J Cardiovasc Surg (Torino)*. 1968;9:403-413.
5. Cooley DA, Bloodwell RD, Hallman GL, Nora JJ. Transplantation of the human heart. Report of four cases. *JAMA*. 1968;205:479-486.
6. Cooley DA, Hallman GL, Bloodwell RD, et al. Human heart transplantation. Experience with twelve cases. *Am J Cardiol*. 1968;22:804-810.
7. Bahnson HT. Transplantation of the heart: reminiscences of the past and inklings of the future. *Ann Thorac Surg*. 1997;64:1561-1563.
8. Dalton ML. The first lung transplantation. *Ann Thorac Surg*. 1995;60:1437-1438.
9. Hoffenberg R. Christiaan Barnard: his first transplants and their impact on concepts of death. *BMJ*. 2001;323:1478-1480.
10. Trulock EP, Christie JD, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report—2007. *J Heart Lung Transplant*. 2007;26:782-795.
11. Etienne B, Bertocchi M, Gamondes JP, et al. Successful double-lung transplantation for bronchioalveolar carcinoma. *Chest*. 1997;112:1423-1424.
12. 2008 Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1998-2007. US Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD.
13. Orens JB, Boehler A, de Perrot M, et al. A review of lung transplant donor acceptability criteria. *J Heart Lung Transplant*. 2003;22:1183-1200.
14. Hosenpud JD, Bennett LE, Keck BM, et al. The Registry of the International Society for Heart and Lung Transplantation: eighteenth official report—2001. *J Heart Lung Transplant*. 2001;20:805-815.
15. Alba AC, Delgado DH. The future is here: ventricular assist devices for the failing heart. *Expert Rev Cardiovasc Ther*. 2009;7:1067-1077.
16. Salters CR Jr, Bailey AL, Whayne TF Jr. Current treatment of heart failure in the USA. *Expert Rev Cardiovasc Ther*. 2010;8:279-290.
17. Tang WH, Francis GS. The year in heart failure. *J Am Coll Cardiol*. 2010;55:688-696.
18. Christie JD, Edwards LB, Aurora P, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-sixth official adult lung and heart-lung transplantation report—2009. *J Heart Lung Transplant*. 2009;28:1031-1049.
19. Based on data obtained from the Organ Procurement and Transplantation Network (OPTN). Available at: <http://optn.transplant.hrsa.gov/latestData/rptStrat.asp>. Accessed February 8, 2010.
20. Mancini D, Lietz K. Selection of cardiac transplantation candidates in 2010. *Circulation*. 2010;122:173-183.
21. Jessup M, Brozena S. Heart failure. *N Engl J Med*. 2003;348:2007-2018.
22. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. *JAMA*. 1996;275:1557-1562.
23. International guidelines for the selection of lung transplant candidates. The American Society for Transplant Physicians (ASTP)/American Thoracic Society(ATS)/European Respiratory Society(ERS)/International Society for Heart and Lung Transplantation(ISHLT). *Am J Respir Crit Care Med*. 1998;158:335-339.
24. Nathan SD. Lung transplantation: disease-specific considerations for referral. *Chest*. 2005;127:1006-1016.
25. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant*. 2006;25:745-755.
26. Kreider M, Kotloff RM. Selection of candidates for lung transplantation. *Proc Am Thorac Soc*. 2009;6:20-27.
27. Thabut G, Christie JD, Ravaud P, et al. Survival after bilateral versus single lung transplantation for patients with chronic obstructive pulmonary disease: a retrospective analysis of registry data. *Lancet*. 2008;371:744-751.
28. Meyer DM, Edwards LB, Torres F, et al. Impact of recipient age and procedure type on survival after lung transplantation for pulmonary fibrosis. *Ann Thorac Surg*. 2005;79:950-957; discussion 7-8.

29. Rinaldi M, Sansone F, Boffini M, et al. Single versus double lung transplantation in pulmonary fibrosis: a debated topic. *Transplant Proc.* 2008;40:2010-2012.
30. Goda A, Lund LH, Mancini DM. Comparison across races of peak oxygen consumption and heart failure survival score for selection for cardiac transplantation. *Am J Cardiol.* 2010;105:1439-1444.
31. Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates—2006. *J Heart Lung Transplant.* 2006;25:1024-1042.
32. Lund LH, Aaronson KD, Mancini DM. Validation of peak exercise oxygen consumption and the Heart Failure Survival Score for serial risk stratification in advanced heart failure. *Am J Cardiol.* 2005;95:734-741.
33. Weiss ES, Nwakanma LU, Patel ND, Yuh DD. Outcomes in patients older than 60 years of age undergoing orthotopic heart transplantation: an analysis of the UNOS database. *J Heart Lung Transplant.* 2008;27:184-191.
34. Schwarz ER, Rosanio S. Religion and the Catholic Church's view on (heart) transplantation: a recent statement of Pope Benedict XVI and its practical impact. *J Relig Health.* 2009. [Epub ahead of print]
35. Lipson DA, Edelman JD, Palevsky HI. Alternatives to lung transplantation: lung volume reduction surgery and continuous intravenous prostacyclin. *Transplant Proc.* 2002;34:1283-1286.
36. Patel N, DeCamp M, Criner GJ. Lung transplantation and lung volume reduction surgery versus transplantation in chronic obstructive pulmonary disease. *Proc Am Thorac Soc.* 2008;5:447-453.
37. Struber M, Lange R, Gummert JF, et al. Alternatives to heart transplantation. Symposium of the "Treatment of End-Stage Heart and Lung Failure" working group on October 22, 2005 in Munich. *Thorac Cardiovasc Surg.* 2007;55(Suppl 2):S147-S167.
38. Nicolini F, Gherli T. Alternatives to transplantation in the surgical therapy for heart failure. *Eur J Cardiothorac Surg.* 2009;35:214-228.
39. Hansky B, Vogt J, Zittermann A, et al. Cardiac resynchronization therapy: long-term alternative to cardiac transplantation? *Ann Thorac Surg.* 2009;87:432-438.
40. Daneshmand MA, Milano CA. Surgical treatments for advanced heart failure. *Surg Clin North Am.* 2009;89:967-999, x.
41. Allen KB, Kelly J, Borkon AM, et al. Transmyocardial laser revascularization: from randomized trials to clinical practice. A review of techniques, evidence-based outcomes, and future directions. *Anesthesiol Clin.* 2008;26:501-519.
42. Salmons S. Cardiac assistance from skeletal muscle: a reappraisal. *Eur J Cardiothorac Surg.* 2009;35:204-213.
43. Shuhaiber JH, Hur K, Gibbons R. The influence of preoperative use of ventricular assist devices on survival after heart transplantation: propensity score matched analysis. *BMJ.* 2010;340:c392.
44. Johnson MR, Meyer KH, Haft J, et al. Heart transplantation in the United States, 1999-2008. *Am J Transplant.* 2010;10:1035-1046.
45. Landsteiner K. On agglutination of normal human blood. *Transfusion.* 1961;1:5-8.
46. Dausset J. The birth of MAC. *Vox Sang.* 1984;46:235-237.
47. Dausset J, Colin M. [Research technic for immunologic thrombo-agglutinins; influence of previous heating of platelet suspensions.]. *Rev Fr Etud Clin Biol.* 1958;3:60-61.
48. Controlling occupational exposure to hazardous drugs. OSHA Technical Manual. Washington, DC: US Department of Labor; 2006.
49. Kobashigawa JA. Controversies in heart and lung transplantation immunosuppression: tacrolimus versus cyclosporine. *Transplant Proc.* 1998;30:1095-1097.
50. Goto T, Kino T, Hatanaka H, et al. FK 506: historical perspectives. *Transplant Proc.* 1991;23:2713-2717.
51. Ransom JT. Mechanism of action of mycophenolate mofetil. *Ther Drug Monit.* 1995;17:681-684.
52. Kobashigawa JA, Patel JK. Immunosuppression for heart transplantation: where are we now? *Nat Clin Pract Cardiovasc Med.* 2006;3:203-212.
53. Martinu T, Howell DN, Palmer SM. Acute cellular rejection and humoral sensitization in lung transplant recipients. *Semin Respir Crit Care Med.* 2010;31:179-188.
54. Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. *J Heart Lung Transplant.* 2002;21:271-281.
55. Bhorade SM, Stern E. Immunosuppression for lung transplantation. *Proc Am Thorac Soc.* 2009;6:47-53.
56. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. *Am J Transplant.* 2006;6:1377-1386.
57. Hunt SA, Haddad F. The changing face of heart transplantation. *J Am Coll Cardiol.* 2008;52:587-598.
58. Suzuki J, Isobe M, Morishita R, Nagai R. Characteristics of chronic rejection in heart transplantation: important elements of pathogenesis and future treatments. *Circ J.* 2010;74:233-239.
59. Schmauss D, Weis M. Cardiac allograft vasculopathy: recent developments. *Circulation.* 2008;117:2131-2141.
60. Meiser BM, Uberfuhr P, Fuchs A, et al. Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. *J Heart Lung Transplant.* 1998;17:782-788.
61. Pham SM, Kormos RL, Hattler BG, et al. A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results. *J Thorac Cardiovasc Surg.* 1996;111:764-772.
62. Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. *J Heart Lung Transplant.* 1999;18:336-345.
63. Taylor DO, Stehlik J, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-sixth official adult heart transplant report—2009. *J Heart Lung Transplant.* 2009;28:1007-1022.
64. Boilson BA, Raichlin E, Park SJ, Kushwaha SS. Device therapy and cardiac transplantation for end-stage heart failure. *Curr Probl Cardiol.* 2010;35:8-64.
65. Van Raemdonck D, Neyrinck A, Verleden GM, et al. Lung donor selection and management. *Proc Am Thorac Soc.* 2009;6:28-38.
66. Van Raemdonck D. Thoracic organs: current preservation technology and future prospects; part 1: lung. *Curr Opin Organ Transplant.* 2010;15:150-155.

67. Christie JD. Lung allograft ischemic time: crossing the threshold. *Am J Respir Crit Care Med.* 2005;171:673-674.
68. Thabut G, Mal H, Cerrina J, et al. Graft ischemic time and outcome of lung transplantation: a multicenter analysis. *Am J Respir Crit Care Med.* 2005;171:786-791.
69. Levine SM. A survey of clinical practice of lung transplantation in North America. *Chest.* 2004;125:1224-1238.
70. Venkateswaran RV, Patchell VB, Wilson IC, et al. Early donor management increases the retrieval rate of lungs for transplantation. *Ann Thorac Surg.* 2008;85:278-286; discussion 86.
71. Yeung JC, Cypel M, Waddell TK, et al. Update on donor assessment, resuscitation, and acceptance criteria, including novel techniques—non-heart-beating donor lung retrieval and ex vivo donor lung perfusion. *Thorac Surg Clin.* 2009;19:261-274.
72. Wolfe RA, Roys EC, Merion RM. Trends in organ donation and transplantation in the United States, 1999-2008. *Am J Transplant.* 2010;10:961-972.
73. Goland S, Czer LS, Kass RM, et al. Use of cardiac allografts with mild and moderate left ventricular hypertrophy can be safely used in heart transplantation to expand the donor pool. *J Am Coll Cardiol.* 2008;51:1214-1220.
74. Forni A, Luciani GB, Chiominto B, et al. Impact of donor quality on outcome of heart transplantation. *Eur J Cardiothorac Surg.* 2010;38:788-794.
75. Harringer W, Haverich A. Heart and heart-lung transplantation: standards and improvements. *World J Surg.* 2002;26:218-225.
76. Venkateswaran RV, Townend JN, Wilson IC, et al. Echocardiography in the potential heart donor. *Transplantation.* 2010;89:894-901.
77. Patel ND, Weiss ES, Nwakanma LU, et al. Impact of donor-to-recipient weight ratio on survival after heart transplantation: analysis of the United Network for Organ Sharing Database. *Circulation.* 2008;118:S83-S88.
78. Jacobs S, Rega F, Meyns B. Current preservation technology and future prospects of thoracic organs. Part 2: heart. *Curr Opin Organ Transplant.* 2010;15:156-159.
79. Stavem K, Bjortuft O, Borgan O, et al. Lung transplantation in patients with chronic obstructive pulmonary disease in a national cohort is without obvious survival benefit. *J Heart Lung Transplant.* 2006;25:75-84.
80. Kozower BD, Meyers BF, Smith MA, et al. The impact of the lung allocation score on short-term transplantation outcomes: a multicenter study. *J Thorac Cardiovasc Surg.* 2008;135:166-171.
81. Merlo CA, Weiss ES, Orens JB, et al. Impact of U.S. Lung Allocation Score on survival after lung transplantation. *J Heart Lung Transplant.* 2009;28:769-775.
82. Baez B, Castillo M. Anesthetic considerations for lung transplantation. *Semin Cardiothorac Vasc Anesth.* 2008;12:122-127.
83. Harik SI, Raichle ME, Reis DJ. Spontaneously remitting spinal epidural hematoma in a patient on anticoagulants. *N Engl J Med.* 1971;284:1355-1357.
84. Horlocker TT, Wedel DJ, Offord KP. Does preoperative antiplatelet therapy increase the risk of hemorrhagic complications associated with regional anesthesia? *Anesth Analg.* 1990;70:631-634.
85. Rao TL, El-Etr AA. Anticoagulation following placement of epidural and subarachnoid catheters: an evaluation of neurologic sequelae. *Anesthesiology.* 1981;55:618-620.
86. Pastor MC, Sanchez MJ, Casas MA, et al. Thoracic epidural analgesia in coronary artery bypass graft surgery: seven years' experience. *J Cardiothorac Vasc Anesth.* 2003;17:154-159.
87. Guillen RV, Briones FR, Marin PM, et al. Lung graft dysfunction in the early postoperative period after lung and heart lung transplantation. *Transplant Proc.* 2005;37:3994-3995.
88. Pierre AF, Keshavjee S. Lung transplantation: donor and recipient critical care aspects. *Curr Opin Crit Care.* 2005;11:339-344.
89. Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. *Am J Surg.* 2005;189:395-404.
90. de Perrot M, Keshavjee S. Lung preservation. *Semin Thorac Cardiovasc Surg.* 2004;16:300-308.
91. Ellman PI, Alvis JS, Tache-Leon C, et al. Hyperoxic ventilation exacerbates lung reperfusion injury. *J Thorac Cardiovasc Surg.* 2005;130:1440.
92. Benditt JO. Surgical options for patients with COPD: sorting out the choices. *Respir Care.* 2006;51:173-182.
93. Hochberg MS, Gielchinsky I, Parsonnet V, et al. Pulmonary inactivation of vasopressors following cardiac operations. *Ann Thorac Surg.* 1986;41:200-203.
94. Stobierska-Dzierzek B, Awad H, Michler RE. The evolving management of acute right-sided heart failure in cardiac transplant recipients. *J Am Coll Cardiol.* 2001;38:923-931.
95. Khan TA, Schnickel G, Ross D, et al. A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients. *J Thorac Cardiovasc Surg.* 2009;138:1417-1424.
96. Santacruz JF, Mehta AC. Airway complications and management after lung transplantation: ischemia, dehiscence, and stenosis. *Proc Am Thorac Soc.* 2009;6:79-93.
97. McCurry KR, Shearon TH, Edwards LB, et al. Lung transplantation in the United States, 1998-2007. *Am J Transplant.* 2009;9:942-958.
98. Beghetti M, Galie N. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. *J Am Coll Cardiol.* 2009;53:733-740.
99. Puri V, Patterson GA. Adult lung transplantation: technical considerations. *Semin Thorac Cardiovasc Surg.* 2008;20:152-164.
100. Kasimir MT, Seebacher G, Jaksch P, et al. Reverse cardiac remodeling in patients with primary pulmonary hypertension after isolated lung transplantation. *Eur J Cardiothorac Surg.* 2004;26:776-781.
101. von Euler C. On the central pattern generator for the basic breathing rhythmicity. *J Appl Physiol.* 1983;55:1647-1659.
102. Bland S, Lazerou L, Dyck G, Cherniack RM. The influence of the "chest wall" on respiratory rate and depth. *Respir Physiol.* 1967;3:47-54.
103. McLroy DR, Pilcher DV, Snell GI. Does anaesthetic management affect early outcomes after lung transplant? An exploratory analysis. *Br J Anaesth.* 2009;102:506-514.
104. Robin ED, Theodore J, Burke CM, et al. Hypoxic pulmonary vasoconstriction persists in the human transplanted lung. *Clin Sci (Lond).* 1987;72:283-287.
105. Sleiman C, Mal H, Fournier M, et al. Pulmonary reimplantation response in single-lung transplantation. *Eur Respir J.* 1995;8:5-9.
106. Ware LB, Golden JA, Finkbeiner WE, Matthay MA. Alveolar epithelial fluid transport capacity in reperfusion lung injury after lung transplantation. *Am J Respir Crit Care Med.* 1999;159:980-988.

107. Ng YL, Paul N, Patsios D, et al. Imaging of lung transplantation: review. *AJR Am J Roentgenol.* 2009;192:S1-S13, quiz S4-S9.
108. Huang HJ, Yusen RD, Meyers BF, et al. Late primary graft dysfunction after lung transplantation and bronchiolitis obliterans syndrome. *Am J Transplant.* 2008;8:2454-2462.
109. Gottlieb J, Szangolies J, Koehnlein T, et al. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. *Transplantation.* 2008;85:36-41.
110. Snell GI, Esmore DS, Williams TJ. Cytolytic therapy for the bronchiolitis obliterans syndrome complicating lung transplantation. *Chest.* 1996;109:874-878.
111. Valentine VG, Bonvillain RW, Gupta MR, et al. Infections in lung allograft recipients: ganciclovir era. *J Heart Lung Transplant.* 2008;27:528-535.
112. Dauber JH, Paradis IL, Dummer JS. Infectious complications in pulmonary allograft recipients. *Clin Chest Med.* 1990;11:291-308.
113. Dummer JS, White LT, Ho M, et al. Morbidity of cytomegalovirus infection in recipients of heart or heart-lung transplants who received cyclosporine. *J Infect Dis.* 1985;152:1182-1191.
114. Sissons JG, Borysiewicz LK. Human cytomegalovirus infection. *Thorax.* 1989;44:241-246.
115. Chou SW. Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. *N Engl J Med.* 1986;314:1418-1423.
116. Wreghitt T. Cytomegalovirus infections in heart and heart-lung transplant recipients. *J Antimicrob Chemother.* 1989;23 (Suppl E):49-60.
117. Valentine VG, Weill D, Gupta MR, et al. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation. *J Heart Lung Transplant.* 2008;27:875-881.
118. Silveira FP, Husain S. Fungal infections in lung transplant recipients. *Curr Opin Pulm Med.* 2008;14:211-218.
119. Engelman R, Shahian D, Shemin R, et al. The Society of Thoracic Surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part II: antibiotic choice. *Ann Thorac Surg.* 2007;83:1569-1576.
120. Shuhaiber JH, Hur K, Gibbons R. The influence of preoperative use of ventricular assist devices on survival after heart transplantation: propensity score matched analysis. *BMJ.* 2010;340:c392.
121. Haddad F, Couture P, Tousignant C, Denault AY. The right ventricle in cardiac surgery, a perioperative perspective: II. Pathophysiology, clinical importance, and management. *Anesth Analg.* 2009;108:422-433.